ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

RCUS Arcus Biosciences Inc

16.97
-0.03 (-0.18%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,430,771
Bid Price
Ask Price
News -
Day High 17.18

Low
12.95

52 Week Range

High
25.47

Day Low 16.43
Share Name Share Symbol Market Stock Type
Arcus Biosciences Inc RCUS NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
-0.03 -0.18% 16.97 19:00:00
Open Price Low Price High Price Close Price Previous Close
16.86 16.43 17.18 16.97 17.00
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
14,863 1,430,771 US$ 16.99 US$ 24,308,688 - 12.95 - 25.47
Last Trade Type Quantity Price Currency
18:58:41 1 US$ 16.95 USD

Arcus Biosciences (RCUS) Options Flow Summary

Overall Flow

Bullish

Net Premium

58k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Arcus Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.54B 90.86M - 117M -307M -3.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Arcus Biosciences News

Date Time Source News Article
6/11/202415:35Business WireArcus Biosciences Announces New Employment Inducement Grants
6/10/202407:30Business WireArcus Biosciences Completes Patient Enrollment in Phase 3..
6/07/202417:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/07/202417:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/07/202417:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
6/06/202415:28Edgar (US Regulatory)Form 8-K - Current report
6/06/202415:05Business WireArcus Biosciences to Participate in the Goldman Sachs 45th..
6/03/202407:18Edgar (US Regulatory)Form 8-K - Current report
6/02/202407:00Business WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab..
6/01/202407:00Business WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus..
5/24/202415:35Business WireArcus Biosciences Announces New Employment Inducement Grants
5/23/202415:59Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RCUS Message Board. Create One! See More Posts on RCUS Message Board See More Message Board Posts

Historical RCUS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week15.7517.1815.11516.12687,0011.227.75%
1 Month17.5017.5614.6916.05660,525-0.53-3.03%
3 Months17.1519.1114.1016.31616,907-0.18-1.05%
6 Months17.7320.3114.1017.07772,962-0.76-4.29%
1 Year20.4725.4712.9517.88806,472-3.50-17.10%
3 Years25.0449.1012.9524.06858,123-8.07-32.23%
5 Years8.5649.106.3024.10695,9818.4198.25%

Arcus Biosciences Description

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Your Recent History

Delayed Upgrade Clock